Heparin Global Market Report 2024

Heparin refers to an anticoagulant type substance that slows the development of blood clots. Heparin is produced by the liver, lungs, and other human tissues, but it can also be produced in a lab. In order to prevent or dissolve blood clots, heparin may be injected into muscle or blood. Heparin is widely used in hospitals to prevent excessive coagulation during cardiac surgery, extracorporeal circulation, or dialysis.

The main types of heparin include unfractionated heparin, low molecular weight heparin (LMWH), and ultra-low molecular weight heparin (ULMWH). The unfractionated heparin (UFH) market refers to a class of fast-acting anticoagulant medication that prevents clot formation by combining with antithrombin. Unfractionated heparin binds to antithrombin and improves its ability to inhibit two of the body's most powerful clotting factors, factor Xa and factor IIa, in minutes. They are sourced from bovine or porcine and administered intravenous or subconscious. they are used in the treatment of venous thromboembolism, atrial fibrillation, renal impairment, coronary artery disease, and others. They are distributed through hospital pharmacies, drug stores or retail pharmacies, and online pharmacies.

The heparin market research report is one of a series of new reports that provides heparin market statistics, including heparin industry global market size, regional shares, competitors with a heparin market share, detailed heparin market segments, market trends and opportunities, and any further data you may need to thrive in the heparin industry. This heparin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The heparin market size has grown strongly in recent years. It will grow from $9.29 billion in 2023 to $9.86 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to increased prevalence of cardiovascular diseases, advances in surgical procedures requiring anticoagulation, growth in the aging population, rise in deep vein thrombosis cases, expansion of applications in renal dialysis.

The heparin market size is expected to see strong growth in the next few years. It will grow to $12.92 billion in 2028 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to growing demand for low-molecular-weight heparin, expansion of heparin use in the treatment of cancer, increasing incidence of venous thromboembolism, development of biosynthetic heparin, increase in the number of emerging markets. Major trends in the forecast period include technological advancements in heparin production, emphasis on the production of safer and more bioavailable heparin, integration of digital technologies in heparin administration, adoption of biosimilars, exploration of heparin alternatives and substitutes.

The increasing prevalence of chronic diseases is significantly driving the growth of the heparin market. Chronic diseases refer to medical conditions, which last more than one year and require constant medical attention or hospitalization for specialized treatment. The changing lifestyle, eating habits, and inappropriate maintenance of body weight are the reasons for chronic conditions and a few more prolonged chronic infections lead to cancerous risk. Growing exposure to the disease has increased the demand for heparin, as they are widely used to make the blood thin during surgeries and various medical treatments. For instance, in July 2021, according to the International Diabetes Federation (IDF), a Belgium-based diabetes organization, the number of persons with diabetes worldwide is predicted to reach 537 million in 2021, 643 million in 2030, and 783 million in 2045. In addition, it was anticipated that 541 million people would have impaired glucose tolerance by 2021. Additionally, it is anticipated that in 2021, nearly 6.7 million people between the ages of 20 and 79 will pass away due to complications from diabetes. Therefore, the increasing prevalence of chronic diseases will drive the growth of the heparin market.

The rising surgical procedure is expected to boost the growth of the heparin market going forward. A surgical procedure refers to a medical intervention or treatment method that involves making incisions or using minimally invasive techniques to access and manipulate the body's tissues or organs. The growing number of surgical procedures necessitates the use of heparin, an anticoagulant, to prevent blood clots during and after surgery, thereby fueling the demand for heparin and driving the growth of the heparin market. For instance, in April 2022, according to a report published by the Aesthetic Society, a US-based organization of board-certified plastic surgeons, surgical procedures saw a 54% increase, with an average of 320 surgical procedures performed by plastic surgeons in 2021. The cost of a typical surgical procedure also rose by 6% on average in 2021. Therefore, the rising surgical procedure is driving the growth of the heparin market.

Product advancement is a key trend gaining popularity in the heparin market. Key players and their research wings are increasingly focusing on developing an advanced and improved heparin or heparin prefilled syringe with precision and convenience to increase their business reach and presence across the globe. For instance, in April 2021, Fresenius Kabi USA, a US-based healthcare company, launched Freeflex IV bags. These are low-concentration sodium heparin in ready-to-use sodium chloride injection. These bags consist of 1,000 USP units of sodium heparin in a 500 mL infusion bag with 0.9% sodium chloride and 2,000 USP units of sodium heparin in a 1,000 mL infusion bag with 0.9% sodium chloride. simple, These heparin bags help reduce medication errors and guarantee patient safety.

Major companies operating in the heparin market are adopting strategic partnerships approach to provide the manufacturing efficiency of bioengineered heparin to individuals, businesses, and governments. Strategic partnerships refer to a process in which companies leverage each other's strengths and resources to achieve mutual benefits and success. For instance, in January 2022, Optimvia, a US-based biopharmaceutical company, partnered with Ginkgo Bioworks, a US-based biotech company. Optimvia officials aim to utilize Ginkgo's cell and enzyme engineering platform to enhance their biosynthetic heparin manufacturing technology. Additionally, they seek to leverage Ginkgo's expertise in fermentation process development to expedite the performance improvements of their heparin production.

In May 2022, Fresenius Kabi, a Germany-based healthcare company, acquired Ivenix Inc. for an undisclosed amount. The integration of Ivenix's top-notch hardware and software solutions with Fresenius Kabi's intravenous fluids and infusion devices will establish an extensive and leading portfolio of high-quality products. This lays a robust and fast-paced foundation to foster sustainable expansion within the high-value MedTech sector. Ivenix Inc. is a US-based medical technology company.

Major companies operating in the in the heparin market report are Baxter International Inc., B. Braun Medical Inc., Dr. Reddy's Laboratories Ltd., Fresenius SE & Co. KGaA, Leo Pharma A/S, Aspen Pharmacare plc, Bioiberica SA, Biomedical Foscama Group, Biovet SA, Changzhou Qianhong Bio-pharma Co. Ltd., CSPC NBP Pharmaceutical Co. Ltd., Gelita Medical AG, Intas Pharmaceuticals Ltd., Nanjing King-friend Biochemical Pharmaceutical Co. Ltd., Opocrin Pharmaceuticals Ltd., Pfizer Inc., Pharma Action Ltd., Rovi Pharma Industrial Services Ltd., Sagent Pharmaceuticals Inc., Sanofi S. A., Shenzhen Hepalink Pharmaceutical Co. Ltd., Sichuan Deebio Pharmaceutical Co. Ltd., Teva Pharmaceuticals Industries Ltd., VAV Life Sciences Inc., Viatris Inc., Wanbang Biopharmaceuticals Co. Ltd., Wockhardt Ltd., Xinbai Pharmaceuticals Co. Ltd., Yino Pharma Co. Ltd., TEGA Therapeutics Inc.

North America was the largest region in the heparin market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the heparin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the heparin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The heparin market consists of sales of enoxaparin, dalteparin, and nadroparin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified)).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.